Joan XXIII University Hospital, Rovira & Virgili University, Tarragona, Spain
Correspondence to: Jordi Rello, MD, PhD, Critical Care Department, Joan XXIII University Hospital, Rovira & Virgili University, 43007 Tarragona, Spain; e-mail: email@example.com
Dr. Schultz raises pertinent concerns about the use of antimicrobial prophylaxis in patients who undergo percutaneous tracheostomies, and disagrees with our interpretation of the findings of ventilator-associated pneumonia (VAP) after percutaneous tracheostomy.1Tracheostomy is an elective surgical procedure in patients with contaminated tracheal mucosa (present in all intubated patients). Therefore, we believe that administration of a β-lactam in the interval of 2 h before the time of surgical incision is a correct indication.2
Antimicrobial prophylaxis should cover potential pathogens to decrease surgery-related infections. The most frequent isolates colonizing our patients prior to tracheotomy were nonfermentative Gram-negative bacilli, with Pseudomonas aeruginosa being identified as the most frequent responsible pathogen. Another patient acquired bacteremia by P aeruginosa during the procedure.1 Based on these findings, we suggested that surgical antimicrobials prescribed for tracheotomy prophylaxis in intubated patients should be active against P aeruginosa.
Dr. Schultz also expressed concern that the incidence of VAP in patients with tracheotomy was not compared to patients not receiving a tracheostoma. The overall incidence of VAP in our ICU was 9.6% of intubated patients in the study period. In the current article, 18.1% of patients acquired VAP after percutaneous tracheotomy. These episodes occurred a median of 7 days after intubation, and most episodes occurred within the first 5 days after the procedure (Table 2).1 This percentage notably exceed the < 1% cumulative risk of acquiring pneumonia per day of mechanical ventilation, which is considered standard in intubated patients.3
Finally, Dr. Schultz indicates that antibiotic use in many patients before the procedure may have predisposed to the high incidence of VAP. However, in a cohort study4focusing on episodes of pneumonia, prior antibiotic use showed a protective effect (relative risk, 0.1; 95% confidence interval, 0.01 to 0.71) within the first days after intubation. These findings agree with observations reported by Sirvent et al5using a prophylactic antibiotic approach. Similarly, Cook et al6estimated that exposure to antibiotics was associated with a risk ratio of 0.37 (95% confidence interval, 0.27 to 0.51) for development of VAP. A recent review article by Bonten et al7confirmed these reports. Antibiotic exposure protects against pneumonia development within the first days of the intubation manipulation, especially against flora present in the colonized airways, suggesting that risk factors vary depending of the exposure to risk (ie, length of ventilation).8
Our opinion on antimicrobial prophylaxis for VAP has been clearly stated in a recent editorial,9 and a randomized clinical trial to assess the effect of single-dose antibiotic administration as prophylaxis for VAP is highly recommended. Unfortunately, such evidence is lacking. Dr. Schultz suggests not using antimicrobial prophylaxis for percutaneous tracheotomies. However, as indicated before, prophylaxis for surgical neck procedures in intubated patients with colonized tracheal mucosa has a level 1 evidence. Until such studies are available, the extremely high incidence of VAP in the first days after the procedure, the distribution of pathogens, and the low predictive value of tracheal aspirates prior to tracheostomy1 suggest that prescription of a single dose of an antipseudomonal agent prior to the percutaneous tracheotomy is the most pertinent policy.
Become a CHEST member and receive a FREE subscription as a benefit of membership.
Individuals can purchase this article on ScienceDirect.
Individuals can purchase a subscription to the journal.
Individuals can purchase a subscription to the journal or buy individual articles.
Learn more about membership or Purchase a Full Subscription.
Institutional access is now available through ScienceDirect and can be purchased at myelsevier.com.
Some tools below are only available to our subscribers or users with an online account.
Download citation file:
Web of Science® Times Cited: 2
Customize your page view by dragging & repositioning the boxes below.
Enter your username and email address. We'll send you a reminder to the email address on record.
Athens and Shibboleth are access management services that provide single sign-on to protected resources. They replace the multiple user names and passwords necessary to access subscription-based content with a single user name and password that can be entered once per session. It operates independently of a user's location or IP address. If your institution uses Athens or Shibboleth authentication, please contact your site administrator to receive your user name and password.